Tong X - Search Results

1

An age-dependent mathematical model of neurofilament trafficking in healthy conditions.

Paris A, Bora P, Parolo S, Monine M, Tong X, Eraly S, Masson E, Ferguson T, McCampbell A, Graham D, Domenici E, Nestorov I, Marchetti L. Paris A, et al. Among authors: tong x. CPT Pharmacometrics Syst Pharmacol. 2022 Apr;11(4):447-457. doi: 10.1002/psp4.12770. Epub 2022 Mar 2. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35146969 Free PMC article.

2

Population pharmacokinetics and standard uptake value ratio of aducanumab, an amyloid plaque-removing agent, in patients with Alzheimer's disease.

Kandadi Muralidharan K, Tong X, Kowalski KG, Rajagovindan R, Lin L, Budd Haberlain S, Nestorov I. Kandadi Muralidharan K, et al. Among authors: tong x. CPT Pharmacometrics Syst Pharmacol. 2022 Jan;11(1):7-19. doi: 10.1002/psp4.12728. Epub 2021 Oct 26. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 34697913 Free PMC article. Clinical Trial.

3

A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen.

Paris A, Bora P, Parolo S, MacCannell D, Monine M, van der Munnik N, Tong X, Eraly S, Berger Z, Graham D, Ferguson T, Domenici E, Nestorov I, Marchetti L. Paris A, et al. Among authors: tong x. CPT Pharmacometrics Syst Pharmacol. 2023 Feb;12(2):196-206. doi: 10.1002/psp4.12890. Epub 2022 Dec 5. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36471456 Free PMC article.

4

Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials.

Muralidharan KK, Kowalski KG, Tong X, Haeberlein SB, Rajagovindan R, Nestorov I. Muralidharan KK, et al. Among authors: tong x. J Pharmacokinet Pharmacodyn. 2023 Feb;50(1):45-62. doi: 10.1007/s10928-022-09839-3. Epub 2023 Jan 4. J Pharmacokinet Pharmacodyn. 2023. PMID: 36600109 Clinical Trial.

5

Population Pharmacokinetic Modeling With Enterohepatic Circulation for AZD3241 in Healthy Subjects and Patients With Multiple System Atrophy.

Tong X, Zhou D, Savage A, Mullen JA, Li Y, Taylor W, Li J, Al-Huniti N, Xu H. Tong X, et al. J Clin Pharmacol. 2018 Nov;58(11):1452-1460. doi: 10.1002/jcph.1134. Epub 2018 Jun 6. J Clin Pharmacol. 2018. PMID: 29873817

6

Population Pharmacokinetic and Exposure-Response Analysis of Selumetinib and Its N-desmethyl Metabolite in Patients With Non-Small Cell Lung Cancer.

Tong X, Xu H, Carlile DJ, Tomkinson H, Al-Huniti N, Zhou D. Tong X, et al. J Clin Pharmacol. 2019 Jan;59(1):112-122. doi: 10.1002/jcph.1295. Epub 2018 Aug 13. J Clin Pharmacol. 2019. PMID: 30102413 Clinical Trial.

7

Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study.

Zhou L, Tong X, Sharma P, Xu H, Al-Huniti N, Zhou D. Zhou L, et al. Among authors: tong x. Basic Clin Pharmacol Toxicol. 2019 Aug;125(2):100-107. doi: 10.1111/bcpt.13209. Epub 2019 Mar 28. Basic Clin Pharmacol Toxicol. 2019. PMID: 30739396 Free article.

8

Correction: TET2-STAT3-CXCL5 nexus promotes neutrophil lipid transfer to fuel lung adeno-to-squamous transition.

Xue Y, Chen Y, Sun S, Tong X, Chen Y, Tang S, Wang X, Bi S, Qiu Y, Zhao Q, Qin Z, Xu Q, Ai Y, Chen L, Zhang B, Liu Z, Ji M, Lang M, Chen L, Xu G, Hu L, Ye D, Ji H. Xue Y, et al. Among authors: tong x. J Exp Med. 2024 Jul 1;221(7):e2024011106032024c. doi: 10.1084/jem.2024011106032024c. Epub 2024 Jun 7. J Exp Med. 2024. PMID: 38847799 Free PMC article. No abstract available.

9

Potential of body mass index as a screening indicator for extracranial-intracranial bypass surgery in patients with symptomatic artery occlusion: a post-hoc analysis of the CMOSS trial.

Lu G, Wang T, Yang F, Sun X, Yang R, Luo J, Tong X, Gu Y, Wang J, Tong Z, Kuai D, Cai Y, Ren J, Wang D, Duan L, Maimaitili A, Hang C, Yu J, Ma Y, Liu S, Jiao L; CMOSS Investigators. Lu G, et al. Among authors: tong x. Int J Surg. 2024 Jun 7. doi: 10.1097/JS9.0000000000001766. Online ahead of print. Int J Surg. 2024. PMID: 38847780

10

Foxp3⁺ Treg control allergic skin inflammation by restricting IFN-γ-driven neutrophilic infiltration and NETosis.

Tong X, Kim SH, Che L, Park J, Lee J, Kim TG. Tong X, et al. J Dermatol Sci. 2024 May 9:S0923-1811(24)00092-6. doi: 10.1016/j.jdermsci.2024.05.002. Online ahead of print. J Dermatol Sci. 2024. PMID: 38845244

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,913 results

Search Page